Emerging Biopharma operate in a highly regulated and competitive landscape, with success hinging on agility, innovation and an often-limited number of therapeutic assets and resources. Indeed, emerging Biopharma in build-out of their organizations.

Key Benefits
- Enhances cross-functional collaboration and alignment
- Enables integrated decision making across the product lifecycle (e.g. indication prioritization, trial design)
- Enables a standardized and streamlined approach to product strategy definition across an organization
- Allows effective utilization of functional resources
- Break down functional siloes through synchronization and development of complementary capabilities
- Enhances culture, effective ways of working and behaviours to increase productivity, efficiency and agility
- Attract, retain and develop the best talent
- Maximizes the benefits for investments and operations, a Biopharma must develop late-stage and go-to-market strategies to support business outcomes and increase speed, innovation and scalability whilst retaining flexibility to allow for agility and innovation
- An effective company culture

Developing Effective Late-Stage And Commercial Asset Strategies
Syneos Health R&D Advisory supports emerging Biopharma in building and integrating high-quality capabilities (organizational structure, governance, compliance, processes, technology landscape and talent) across multiple functions, vital to streamlining Development and maximizing asset return on investment. As a Biopharma builds out its organizational scale-up operations, we define three critical challenges on the journey to delivering medicines to patients.

Critical Challenges Facing Emerging Biopharma:

1. Scale-up of operations and build out of capabilities marks the beginning of an extended period of transformational change. The rapid influx of talent (e.g. Development and Commercial Leadership and Expert Practitioners) can dramatically shift company culture and ways of working. Initiatives must be prioritized and managed to increase immediate productivity, and reduce the resistance that can spread across an organization and disrupt team operations, innovation and potentially delay progress to market.

2. Success hinges on agility, innovation and an often-limited number of therapeutic assets and resources. Indeed, emerging Biopharma operate in a highly regulated and competitive landscape, with success hinging on agility, innovation and an often-limited number of therapeutic assets and resources.

3. To support late-stage Development, commercialization and expanding operations, a Biopharma must effectively prioritize, invest in, resource and implement capability building initiatives across multiple functions, while maintaining quality and compliance. Timing, prioritization and seamless integration are critical. Furthermore, ensuring the appropriate level of structure for effective operations, whilst retaining flexibility to allow for agility, innovation and scalability, is key.

Syneos Health R&D Advisory supports emerging Biopharma to deliver medicinal therapies to patients, nurture a culture of innovation and compliance, and build a platform for future growth.

How Can We Help?

Syneos Health R&D Advisory supports emerging Biopharma to deliver medicinal therapies to patients, nurture a culture of innovation and compliance, and build a platform for future growth.

Supporting Emerging Biopharma
Syneos Health R&D Advisory supports emerging Biopharma to deliver medicinal therapies to patients, nurture a culture of innovation and compliance, and build a platform for future growth.

Syneos Health R&D Advisory has a depth of experience and expertise in supporting emerging Biopharma in build-out of their organizations. We look forward to continuing the conversation through release of our thinking on key challenges and best practices in this space in the near future!